Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Cash Flows from Operating Activities:
Net loss	$ (19,386)	$ (849)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	972	977
Loss on extinguishment of debt	27,479	0
Gain on derecognition of accrued expenses and purchase price guarantee	(8,300)	0
Gain from change in fair value of hybrid financial instruments	(11,926)	(5,351)
(Gain) loss from change in fair value of derivative liability - warrants	(11,347)	12,223
(Gain) loss from change in fair value of derivative liability - Series C and D preferred stock and debentures	13,035	(15,715)
Stock-based compensation expense	14	66
Bad debt expense	457	19
Interest expense added to liabilities	4,406	3,378
Impairment loss on cash surrender value of life insurance policy	527	0
Changes in operating assets and liabilities
Decrease (increase) in trade accounts receivable	0	(348)
Decrease in inventories	0	112
Decrease in prepaid expenses and other assets	63	99
Decrease in value of life insurance policies	0	86
Increase in accounts payable and accrued liabilities	555	447
Increase in deferred revenue and other current liabilities	1,915	403
Net cash used in operating activities	(1,536)	(4,453)
Cash Flows from Investing Activities:
Acquisition of property and equipment	(3)	(2)
Proceeds received from life insurance policy	126	0
Net cash provided by (used in) investing activities	123	(2)
Cash Flows from Financing Activities:
Repayment of convertible debt instruments	(450)	0
Borrowings under convertible debentures	2,500	4,410
Net cash provided by financing activities	2,050	4,410
Effect of exchange rate changes on cash	(56)	(5)
Net change in cash and cash equivalents	581	(50)
Cash and cash equivalents, beginning of year	30	80
Cash and cash equivalents, end of year	611	30
Supplemental cash flow information:
Interest paid during the period	31	1,001
Series C preferred stock converted to common stock	878	9,874
Series D preferred stock converted to common stock	2,342	1,951
Convertible debentures converted to common stock	17,138	4,307
Shares issued for acquisition of patent rights	$ 0	$ 350